How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

14,624 results for

Systemic Lupus Erythematosus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Evidence of a distinct group of Black African patients with systemic lupus erythematosus Full Text available with Trip Pro

Evidence of a distinct group of Black African patients with systemic lupus erythematosus The autoimmune disease systemic lupus erythematosus (SLE) occurs more frequently in patients of African descent with high morbidity and mortality. Current SLE diagnostic criteria including antinuclear antibody (ANA) reactivity are derived largely from non-African populations. This study characterises ANA reactivity patterns and relates them to SLE clinical presentation in Black African patients.Sera from

2018 BMJ global health

42. Catalytic antibodies in patients with systemic lupus erythematosus Full Text available with Trip Pro

Catalytic antibodies in patients with systemic lupus erythematosus Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from

2018 European journal of rheumatology

43. Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome Full Text available with Trip Pro

Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome To describe a triad of fibrous histiocytoma, Systemic Lupus Erythematosus and Sero-positive Sjögren's Syndrome.This case was diagnosed first as bilateral fibrous histiocytoma of cheeks, which on further investigations proved to be a triad of Systemic Lupus Erythematosus, Fibrous histiocytoma and Sero-positive Sjögren's Syndrome.Association between fibrous histiocytoma, Systemic Lupus (...) Erythematosus and Sero-positive Sjögren's Syndrome has been known before, but fibrous histiocytoma as first presentation in the triad has not been reported.

2018 American journal of ophthalmology case reports

44. Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study Full Text available with Trip Pro

Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study Current guideline-recommended screening for pulmonary hypertension in patients with systemic sclerosis has not been evaluated in systemic lupus erythematosus (SLE), which is disproportionately prevalent in Asians. This multicentre, cross-sectional screening study aims to study the prevalence of pulmonary hypertension among SLE patients using these guidelines, and identify independent

2018 ERJ open research

45. Musculoskeletal involvement and ultrasonography update in systemic lupus erythematosus: New insights and review Full Text available with Trip Pro

Musculoskeletal involvement and ultrasonography update in systemic lupus erythematosus: New insights and review Ultrasonography has been rarely used to measure musculoskeletal and joint activity in systemic lupus erythematosus (SLE). The aim of this review is to discuss the utility and reliability of this non-invasive diagnostic tool for the assessment of joint disease in SLE patients. In the last decade, several reports have highlighted the role of ultrasonography for a better evaluation

2018 European journal of rheumatology

46. Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association Full Text available with Trip Pro

Inflammatory myopathy and autoimmune hepatitis in a patient with a flare of systemic lupus erythematosus: An exceptional association Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide clinical expression, and musculoskeletal manifestations are the most frequent manifestations of the disease. Digestive manifestations, however, are less prevalent, appearing in only 2%-30% of the patients. Among these cases, the association of SLE with autoimmune hepatitis (AIH) is considered

2018 European journal of rheumatology

47. TNF-like weak inducer of apoptosis (TWEAK) and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A systemic review and Meta-Analysis

TNF-like weak inducer of apoptosis (TWEAK) and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A systemic review and Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

48. Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program. Full Text available with Trip Pro

Dietary omega polyunsaturated fatty acid intake and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Program. To examine associations between dietary intake of omega-3 (n-3; generally anti-inflammatory) and omega-6 (n-6; generally pro-inflammatory) fatty acids and patient-reported outcomes in systemic lupus erythematosus (SLE).This study was based on the population-based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort (...) . Estimates of n-3 and n-6 intake were derived from Diet History Questionnaire II items (DHQ II; past year with portion size version). Patient-reported outcomes included self-reported lupus activity (Systemic Lupus Activity Questionnaire/SLAQ). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n-3 and n-6, as well as the n-6:n-3 ratio, and patient-reported outcomes.Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4

2019 Arthritis care & research

49. Musculoskeletal Ultrasound in Systemic Lupus Erythematosus: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group. (Abstract)

Musculoskeletal Ultrasound in Systemic Lupus Erythematosus: Systematic Literature Review by the Lupus Task Force of the OMERACT Ultrasound Working Group. To identify and synthesize the best available evidence on the application of musculoskeletal ultrasound (US) in patients with systemic lupus erythematosus (SLE) and to present the measurement properties of US in different elementary lesion and pathologies.A systematic literature search of PubMed, Embase and the Cochrane Library was performed

2019 Journal of Rheumatology

50. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. (Abstract)

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. We evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE).LLDAS attainment, discrimination between belimumab and placebo arms, and the effects in subgroups with high disease activity (...) at recruitment were evaluated at week 52 using appropriate descriptive statistics, χ2 test and logistic regression.At week 52, for belimumab 10 mg/kg, 17.0% and 19.3% of patients who achieved a Systemic Lupus Erythematosus Responder Index-4 also attained LLDAS in BLISS-52 and BLISS-76, respectively. Significantly more patients attained LLDAS on belimumab 10 mg/kg compared with placebo (12.5% vs 5.8%, OR 2.32, p=0.02 for BLISS-52; 14.4% vs 7.8%, OR 1.98, p=0.04 for BLISS-76). In a subgroup analysis

2019 Annals of the Rheumatic Diseases Controlled trial quality: uncertain

51. Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus. (Abstract)

Achieving Lupus Low Disease Activity State (LLDAS-50) is associated with both reduced damage accrual and mortality in patients with Systemic Lupus Erythematosus. To assess the impact of achieving Lupus Low Disease Activity State (LLDAS-50) on damage accrual and mortality in an inception cohort of patients with Systemic Lupus Erythematosus (SLE).We used data from the Tromsø Lupus Cohort, a longitudinal population-based study of all SLE patients in the 2 northern-most counties in Norway. LLDAS (...) was defined as a) SLEDAI-2K ≤4, with no activity in major organ systems b) no new features of lupus disease activity c) current prednisolone (or equivalent) dose ≤7.5 mg daily, and, d) well tolerated standard maintenance doses of immunosuppressive drugs.A total of 69 patients (33.5%) spent at least half of their follow up time in LLDAS, thus achieving LLDAS-50, and these patients had both significantly better survival and lower risk of developing severe SDI over time. After correcting for age and sex

2019 Arthritis care & research

52. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a multi-ethnic, multinational Latin-American Lupus Cohort. (Abstract)

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a multi-ethnic, multinational Latin-American Lupus Cohort. To determine the predictors of remission and low disease activity state (LDAS) in systemic lupus erythematosus (SLE).Three disease activity states were defined: Remission=SLEDAI=0 and prednisone≤5mg/d and/or immunosuppressants (maintenance dose); LDAS=SLEDAI≤4, prednisone≤7.5mg/d and/or immunosuppressants (maintenance dose); and non

2019 Journal of Rheumatology

53. The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study Full Text available with Trip Pro

The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study . To assess the role of LN as a risk factor for myocardial infarction (MI), stroke and cardiovascular mortality (CVM) in patients with SLE.. The study was conducted using individual-level data from multiple nationwide registers. We identified a cohort of patients diagnosed with SLE and further determined if they had a diagnosis

2017 EvidenceUpdates

54. Genomics of Systemic Lupus Erythematosus: Insights Gained by Studying Monogenic Young-Onset Systemic Lupus Erythematosus. (Abstract)

Genomics of Systemic Lupus Erythematosus: Insights Gained by Studying Monogenic Young-Onset Systemic Lupus Erythematosus. Systemic lupus erythematosus (SLE) is a systemic, autoimmune, multisystem disease with a heterogeneous clinical phenotype. Genome-wide association studies have identified multiple susceptibility loci, but these explain a fraction of the estimated heritability. This is partly because within the broad spectrum of SLE are monogenic diseases that tend to cluster in patients

2017 Rheumatic Diseases Clinics of North America

55. Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) Full Text available with Trip Pro

Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS) To assess the impact of disease activity on health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE).Cross-sectional study of patients included in the Swiss SLE Cohort Study between April 2007 and June 2014. HRQoL outcomes were based on the Medical Outcome Study Short Form 36 (SF-36). Disease (...) component summary (PCS) 43.7 [37.0-52.8] compared to 49.1 [38.4-55.6], respectively (p < 0.05). Increase in SELENA-SLEDAI or increase in PGA were negatively correlated with PCS and/or MCS. After adjusting for gender, age and disease duration, disease activity impacted on both PCS and MCS and all subscales except general health. Active lupus nephritis and musculoskeletal involvement were associated with physical limitations and emotional problems, increased bodily pain and poor social functioning. Low

2017 BMC immunology

56. Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China Full Text available with Trip Pro

Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX: Clinical Features and Survival of Childhood-Onset Systemic Lupus Erythematosus in China Approximately 15-20% cases of systemic lupus erythematosus (SLE) are diagnosed in children. There have been a few studies reporting the epidemiological data of pediatric-onset SLE (cSLE) in China, neither comparing the differences between cSLE and adult-onset SLE (aSLE). The aim of this study was to describe the impact of age (...) was the risk factor for organ damage in lupus patients (hazard ratio 0.335 [0.170-0.658], P = 0.001). The survival curves between the cSLE and aSLE groups had no significant difference as determined by the log-rank test (0.557, P = 0.455).cSLE in China has different clinical features and more inflammation than aSLE patients. Damage may be less in children and there is no difference in 5- year survival between cSLE and aSLE groups.

2017 Chinese medical journal

57. Self-Reported Physical Activity Is Associated with Lupus Nephritis in Systemic Lupus Erythematosus: Data from KORean Lupus Network (KORNET) Registry Full Text available with Trip Pro

Self-Reported Physical Activity Is Associated with Lupus Nephritis in Systemic Lupus Erythematosus: Data from KORean Lupus Network (KORNET) Registry The aim of this study was to identify the associations among physical activity, disease activity, and organ damage in patients with systemic lupus erythematosus (SLE).A total of 415 patients with SLE were consecutively enrolled from the KORean lupus Network (KORNET) registry. This registry assessed clinical features, disease activity [Systemic (...) Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)], and organ damage [Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI)] upon enrollment in the study. Self-reported physical activity was measured by the International Physical Activity Questionnaire. Statistical analyses were conducted using the Mann-Whitney U test and multivariate logistic regression analysis.A significant difference in vigorous activity was noted between

2018 Yonsei medical journal

58. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del Lupus</i>)-Pan-American League of Associations of Rheumatolo Full Text available with Trip Pro

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatolo Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when (...) therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised

2018 Annals of the Rheumatic Diseases

59. Antinuclear Antibody Testing for Systemic Lupus Erythematosus or Connective Tissue Disease

Antinuclear Antibody Testing for Systemic Lupus Erythematosus or Connective Tissue Disease Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid (...) for Systemic Lupus Erythematosus or Connective Tissue Disease: Clinical Effectiveness and Guidelines DATE: 12 March 2015 RESEARCH QUESTIONS 1. What is the clinical effectiveness of antinuclear antibody testing in patients without symptoms for systemic lupus erythematosus or other connective tissue diseases? 2. What are the evidence-based guidelines for antinuclear antibody testing in patients without symptoms for systemic lupus erythematosus or other connective tissue diseases? KEY FINDINGS Three

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

60. Systemic Lupus Erythematosus: What are the orofacial manifestations and dental considerations?

Systemic Lupus Erythematosus: What are the orofacial manifestations and dental considerations? Systemic Lupus Erythematosus: What are the orofacial manifestations and dental considerations? - National Elf Service Search National Elf Service Search National Elf Service » » » » Systemic Lupus Erythematosus: What are the orofacial manifestations and dental considerations? Jun 24 2020 Posted by Systemic lupus erythematosus (SLE) is an autoimmune disease, predominately affecting females, that has (...) studies populations. The need of prospective studies appears mandatory to clearly determine the etiology of the association between SLE and oral disease Systemic lupus erythematosus is a multisystem autoimmune disease with a wide spectrum of clinical presentations, partly linked to treatment-related adverse effects, but also related to the disease itself. Orofacial involvement plays an important role in the disease course, both for the diagnosis and for treatment The findings in this review article

2020 The Dental Elf

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>